Palisade Bio (PALI) EBIT Growth (3y) (2013 - 2026)

Palisade Bio (PALI) EBIT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Palisade Bio 985.76 -132.63 Mn - -61.98%

Historic Data

Download Data
DateValue
Mar 31, 2026 -61.98%
Dec 31, 2025 -37.40%
Sep 30, 2025 12.84%
Jun 30, 2025 7.33%
Mar 31, 2025 15.93%
Dec 31, 2024 5.65%
Sep 30, 2024 -6.01%
Jun 30, 2024 49.58%
Mar 31, 2024 -23.41%
Dec 31, 2023 0.94%
Sep 30, 2023 -27.66%
Jun 30, 2023 -25.15%
Mar 31, 2023 -8.31%
Dec 31, 2022 -21.74%
Sep 30, 2022 -27.60%
Jun 30, 2022 -23.02%
Mar 31, 2022 -16.54%
Dec 31, 2021 -30.67%
Sep 30, 2021 -13.14%
Jun 30, 2021 -153.25%